New partership to help unemployed people get back into the labor force faster.

New partership to help unemployed people get back into the labor force faster.

New partership to help unemployed people get back into the labor force faster. Monsenso enters a partnership with Empano, a private player in psychology and psychiatry services. Together, Monsenso and Empano offer a solution for the Danish municipalities to support unemployed people suffering with stress and depression in their return to work process. Initially, the solution will be implemented in Guldborgssund Municipality, Denmark, in September 2020.

“In a situation with historically high unemployment, we are pleased to offer a solution that can help get more Danes back into the labor force faster. It’s always difficult to be outside the labor force, and even more so if you suffer from stress and depression. “Therefore, we are pleased to offer a solution to municipalities that can help unemployed people suffering with stress and depression get back to work” says CEO Thomas Lethenborg.

“The municipalities are facing a major task due to the increased unemployment we are seeing in the wake of Covid-19. The combination of our services in the psychology and psychiatry services, and Monsenso’s platform to support follow-up and data collection is unique in the market and we are convinced that the service can help municipalities to proactively help the larger group of unemployed ” says Director Camilla Stokholm Bjørkman from Empano. 

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Monsenso is ISO 13485 certified

Monsenso is ISO 13485 certified

Quality Policy and Standards

As a technology leader in mobile health (mHealth) solutions for mental health, Monsenso is ISO 13485 certified. ISO 13485 is the gold standard for medical device companies to ensure the quality, safety and efficacy of products in the medical device field. This certification ensures that the product in question, consistently meets customer requirements and regulatory requirements applicable to medical devices and other related services.

Monsenso adheres to the highest security standards. Beyond, being ISO 13485, Monsenso holds the ISO 27001 certifications, a TGA certification and class 1 CE mark.” says Thomas Lethenborg, CEO at Monsenso.

For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com

Monsenso signs agreement to support global pharmaceutical across Europe

Monsenso signs agreement to support global pharmaceutical across Europe

Following a year-long collaboration, Monsenso signs a three-year +10 mio DKK agreement with a global pharmaceutical company.

Monsenso’s mobile health solution will be used for real-world data collection across two studies in connection with the launch of a new drug for depression treatment. The studies are expected to start in the first half of 2021 and will run over a three-year period, covering up to 2250 patients and 120 clinicians across Belgium, the Netherlands, the United Kingdom, Switzerland, Italy, Spain, Denmark, Sweden and France.

In connection with the two studies, Monsenso’s solution will be used to collect data from patients and their relatives through clinical questionnaires, daily self-assessments and behavioral data from smartphones and wearables.

In addition, the patients will be offered in-app study information and can receive reminders about medication and consultations with their clinician. Monsenso’s unique mobile health solution will in this way help increase the quality of clinical studies with real-time data collection while also facilitating better communication between patients, caregivers and clinicians.

“We are very pleased to expand our collaboration with this global pharmaceutical company and to participate in these projects. Depression is a leading burden of disease for society, and it has severe consequences for patients and their family caregivers, so we are proud to contribute to solving this problem” says Thomas Lethenborg, CEO of Monsenso. “In addition, the project will support our European expansion and our focus on partnering with pharmaceuticals, which is in line with our strategy”. 

The project will not affect Monsenso’s previously communicated plans and guidance for the 2020 financial year.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

GoGreen research project helps Monsenso enter new markets

GoGreen research project helps Monsenso enter new markets

GoGreen research project helps Monsenso expanding into new markets. Monsenso is pleased to announce that it is partnering with a pan-European consortium in the Go Green Routes research project supported by the Horizon 2020 programme. The consortium has been granted EUR 10.49 million from the EU to develop innovative solutions that foster mental health and well-being by optimising human-nature interactions for citizens. These innovations will increase the uptake and acceptability of nature-based solutions across the trial cities Burgas, Lahti, Limerick, Tallinn, Umea and Versailles.

Monsenso’s solution will be further developed and used to both encourage green nature-based choices and to monitor citizens’ mental health to help better understand the health impact of nature-based choices for people in cities. Monsenso’s share of the project contribution will be EUR 253.000.

Participating in a project that combines nature-based solutions, green choices and mental health and well-being is very exciting for Monsenso. A lot of focus and investment is going into green solutions and technologies these years, and this could represent a great potential for us. Moreover, the project will expand our international network and help bring the Monsenso solution into new markets”. says Thomas Lethenborg, CEO of Monsenso. 

The project will start in September 2020 and is coordinated by the University of Limerick. The project run for four years and includes 40 partners across 18 countries, among others Mental Health Europe, King’s College London, Technical University Munich, Manchester Metropolitan University and universities in Tallinn, Aachen, Torino, Antwerpen, Versailles and Inland Norway as well as the trial cities.

We envisage that GOGREEN ROUTES will translate cutting edge research into impactful solutions for cities health, mobility and ecology” says Dr Tadhg MacIntyre, lecturer in psychology at the University of Limerick and project lead coordinator.

This project is funded by the European Union’s Horizon 2020 framework programme under grant agreement No 869764.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Reference
GOGREEN ROUTES Project Outline, click here.

Monsenso receives ISO 27001 re-certification

Monsenso receives ISO 27001 re-certification

Copenhagen, Denmark – 23 July 2020. Monsenso recently received the ISO 27001 re-certification. This is the international standard that describes best practices for an information security management system (ISMS). The company had originally received the ISO 27001 certification in August 2017, and since the certification is valid for three years, the re-certification was due this summer.

Compliance with this certification validates that Monsenso has implemented comprehensive information security practices that protect its users and their information in accordance with internationally recognised standards.

The ISO 27001 standard ensures the secure management of customers’ information, intellectual property, and third party information by establishing methodologies and meeting key objectives for implementing information security.

Monsenso underwent an in-depth assessment by a third-party auditor to validate compliance with this standard. Maintenance of the certification requires an annual review and a three-year re-certification, giving Monsenso users confidence that their data is continuously protected under these standards.

With regards to obtaining the ISO 27001 certification, Thomas Lethenborg, CEO at Monsenso, commented “Data security is critical when dealing with medical information, and the ISO 27001 certification provides our users with the highest level of protection for their most sensitive data.”

Monsenso Clinic already holds a CE Mark and TGA Certification.

Click on the link to read the press release in Danish.

For additional information, please contact:

Jennifer Highland
Marketing
Monsenso
+45 30 25 15 26
marketing@monsenso.com

Research project HedaX aims to develop a new platform to securely handle health data

Research project HedaX aims to develop a new platform to securely handle health data

Copenhagen Demark – 22 June 2020. The Research Project HedaX received EUR 16 million from the Danish Innovation Fund to develop a digital platform that can securely collect and exchange health data. This tool will provide researchers with the basis to offer better, personalised medicine.

In the current world situation, the proliferation of a new virus has had fatal consequences for society. However, the spread of infection can be curbed by collecting and exchanging data; this data exchange needs to take place without compromising an individual’s privacy. The Research Project HedaX aims to develop a digital solution that collects and exchanges personal health data anonymously and securely.

 

THE DANISH RESEARCH PROJECT HEDAX HAS A SOLUTION

The Research Project HedaX project will initially test the solution in two pilot projects that involve 1,000 cancer patients and 1,000 people with bipolar disorder. The goal is to use this new health data to gain insight into how the treatment is helping patients, and to demonstrate that sharing personal health data can help develop better-personalised care.

The Research Project HedaX involves ten public and private partners that will work together to develop a platform that ensures health data is securely collected and exchanged between individuals, healthcare professionals, and researchers.

The data collected by the solution would include an individual’s medical history, medication compliance, and personal sensor data, which is the data collected by most fitness apps.

The analysis of this data should provide a basis for better and cheaper treatment in the form of personalised medicine.  The platform should also be used to monitor the spread of an infection confidentially, so that it is possible to identify where the infected individuals are located, without knowing who they are.

The newly developed platform should include the latest and most secure data encryption from various sources, such as the individual’s mobile phone, to the Social Security Registry and government’s databases.

Individuals should be able to get an overview and insight into the data that is being used, the entity using the data, and its purpose.

The Monsenso mHealth solution will be used to collect objective and subjective data from 1,000 individuals with bipolar disorder. The data will be anonymised and incorporated to the Registry data and EMR data to provide a new foundation for deep phenotyping, personalised medicine and overall understanding of real-life drug effectiveness.

“During the past five years, the Monsenso mHealth solution has been used in different research projects around the world to securely collect and share data between individuals with a mental illness and their healthcare professional. The scope of the project is rather familiar to us, and we are looking forward to participating in this project and helping individuals maintain their privacy while their data is safely collected and used to improve future treatments,” says Thomas Lethenborg, CEO of Monsenso.

 

The HedaX partners:

Secata is a pioneer in the commercial application of advanced encryption for data sharing. Their technology is based on more than 20 years of groundbreaking research in secure multiparty computation.

The Data for Good Foundation is a newly established foundation with non-profit purposes, based on GDPR legislation, that helps individuals share and retain control over their data.

DataFair is an entrepreneurial company with a particular focus on data-driven innovation and personalised medicine based on Denmark’s reliable health data.

The Alexandra Institute works with applied research in the field of digitisation and has helped develop encryption technology within the health sector.

The Danish Cancer Society is Denmark’s largest patient organisation.

Lundbeck is a Danish pharmaceutical company working on the development of pharmaceuticals within psychiatry and neurology.

Monsenso is a Danish company that develops mobile health solutions that help individuals collect information on their mobile phone to use it for prevention and treatment.

The Danish Capital Healthcare Region (Region H) offers Monsenso’s solution to patients within psychiatry.

DPO Management advises on secure and confidential sharing of data with a focus on GDPR rules.

Clinical Epidemiological Department at Aarhus University works with analysis of health data.

To read the Danish version, click here. 

For additional information contact:

Jennifer Highland
Marketing Consultant
marketing@monsenso.com
Monsenso